| |
RA group |
| Age [years] |
56.6 (3.6) |
| Body mass [kg] |
69.6 (11.7) |
| Body height [cm] |
159.9 (4.6) |
| BMI [kg/m2] |
27.2 (4.6) |
| Waist circumference [cm] |
89.4 (11.3) |
| Menopause [years] |
50.0 (49.0-53.0) |
| Disease duration [years] |
11.3 (7.27) |
| DAS28 |
5.13 (1.03) |
| Rheumatoid Factor positive n (%) |
26 (74) |
| ESR [mm/h] |
30.0 (15.0-52.0) |
| hsCRP [mg/l] |
12.0 (8.0-28.0) |
| Interleukin 6 [pg/ml] |
8.51 (5.0-16.1) |
| Resistin [ng/ml] |
16.29 (11.17-25.10) |
| Osteocalcin [ng/ml] |
2.74 (1.95) |
| Glucose [mmol/l] |
4.96 (0.73) |
| Insulin [mIU/ml] |
10.00 (7.88-13.39) |
| HOMA-IR |
2.23 (1.64-2.75) |
| IGF-1 [mg/ml] |
165.76 (36.00) |
| IGFBP-3 [mg/ml] |
3894.29 (631.86) |
| IGF-1/IGFBP-3 |
0.04 (0.01) |
| Current treatment
|
|
| DMARDs n (%) |
35 (100) |
| Prednisolone n (%) |
21 (60) |
| Prednisolone [mg/daily] |
6.3 (2.5) |
Results are expressed as mean (SD) for normally distributed variables and as
median (interquartile range) for non-normally distributed variables; BMI, body mass
index; DAS28, disease activity score; ESR, erythrocyte sedimentation rate; hsCRP,
high sensitivity C-reactive protein; HOMA-IR,, homeostasis model assessment of
insulin resistance; IGF-1, insulin-like growth factor-1; IGFBP-3, insulin-like growth
factor binding protein-3; DMARDs, disease-modifying anti-rheumatic drugs |
